Background {#Sec1}
==========

Pancreatic cancer (PC) is the fourth most common cause of cancer-related death in the Western world, although it only represents 3% of all new cancer cases \[[@CR1], [@CR2]\]. Most cases are pancreatic ductal adenocarcinomas (PDAC). Due to locally advanced or metastatic disease, only 20% of all patients diagnosed with PC are accessible to radical surgical treatment, and thereby have the potential for long-term survival \[[@CR3], [@CR4]\]. However, even in this group, the 5-year survival is only 20% due to the high recurrence rate \[[@CR5], [@CR6]\].

PC located in the head of the pancreas constitutes the majority (60--70%) of the group of cancers in the region, which also includes of ampullary adenocarcinomas (A-AC), accounting for 15--25%; and duodenal cancers (DC); and distal common bile duct (CBD) cancers, each accounting for approximately 10%\[[@CR6]\]. The distribution of the different types of the periampullary cancers is variously reported, probably due to the complexity of the periampullary anatomy and histopathology. The 5-year survival rate after surgery is 45--55% for A-AC and DC \[[@CR7], [@CR8]\] and approximately 25% for distal CBD cancers \[[@CR6]\].

Cancer antigen 19--9 (CA 19--9, also named carbohydrate antigen 19--9 and sialylated Lewis antigen) is the most widely used biomarker for patients with PC. Serum CA19-9 alone is insufficient as a diagnostic biomarker, although it may have prognostic value in the absence of cholestasis \[[@CR9]\]. There is an obvious need for better biomarkers in PC, and microRNAs (miRNAs, miRs) could be interesting in this regard.

MiRNAs are small (18--24 nucleotides) non-coding RNAs that regulate gene expression post-transcriptionally by binding to messenger RNA molecules through nucleotide complementarity \[[@CR10], [@CR11]\]. MiRNAs regulate critical cellular processes such as differentiation, proliferation, apoptosis, and metastasis \[[@CR12]--[@CR16]\]. MiRNAs are stable and analyzable in formalin-fixed paraffin-embedded (FFPE) tissue, which is suitable for analysis \[[@CR17], [@CR18]\]. So far, 2603human miRNA sequences have been discovered and the number is increasing \[[@CR19]\].

The expression patterns of miRNAs can be combined into profiles that are specific for a given type of tissue or disease. Several specific miRNA expression profiles in PC tissue have been described, with a promising consistency between studies and different array or PCR platforms. The expressions of miR-15b, −21, −95, −103, −107, −122, −135b, −148a, −155, −190, −196a, −200, −203, −210, −216b, −217, −221, −222, and miR-375 differ between PC and normal pancreas or chronic pancreatitis \[[@CR20]--[@CR28]\]. Furthermore, miRNA expression profiling indicates a close relationship between PDAC and A-AC \[[@CR27]\]. Specific miRNAs have also been suggested as prognostic biomarkers in several cancers, including PC \[[@CR23], [@CR29]--[@CR32]\].

The aim of the present study was to validate previously described diagnostic and prognostic miRNA expression profiles for PDAC and A-AC in FFPE specimens.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

### Diagnostic miRNA study {#Sec4}

FFPE tumor specimens (*n* = 359 including an internal control) were obtained from patients who underwent resection with radical intent for the following diagnoses: PDAC (*n* = 165), A-AC (*n* = 59), DC (*n* = 6), distal CBD cancer (*n* = 21), chronic pancreatitis (CP) (*n* = 39), gastric cancer (GC) (*n* = 20), serous cyst adenoma (*n* = 2), and no cancer (*n* = 4; cysts or fibrosis that could not be classified as normal pancreas or pancreatitis and did not have any malignant foci) and healthy subjects (HS) (*n* = 35). The pancreatic and periampullary specimens came from patients who had undergone pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy between 2004 and 2011 in Denmark (Herlev Hospital *n* = 9; Rigshospitalet *n* = 198), Germany (Heidelberg *n* = 69), and Norway (Bergen *n* = 55). The chronic pancreatitis specimens came from Copenhagen (*n* = 5) and Heidelberg (*n* = 34). All normal pancreas tissue was obtained from Heidelberg from organ donors or patients with traumatic pancreatic lesions leading to resection of healthy pancreatic tissue. The Danish patients were included in the BIOPAC Study (BIOmarkers in patients with Pancreatic Cancer). The gastric cancers came from patients who had undergone surgery at Gentofte Hospital. An experienced pathologist reassessed all samples to select the most representative part of the specimen, and tumors were classified and graded according to the World Health Organization criteria \[[@CR33]\].

### Prognostic miRNA study {#Sec5}

One hundred fifty-seven FFPE tumor specimens were analyzed from patients who underwent surgery with radical intent for PDAC (*n* = 103) and A-AC (*n* = 54). The patients were included in the BIOPAC Study at Rigshospitalet in Denmark. Inclusion criteria were age ≥ 18 years and histologically verified PC in a resected specimen. After surgery, the majority of the patients (87%) were treated with adjuvant gemcitabine for 6 months or until disease recurrence.

Patient characteristics are shown in Table [1](#Tab1){ref-type="table"}.Table 1Characteristics of the Danish patientsCharacteristicPDAC\
N = 110A-AC\
N = 59Duodenal cancer\
N = 6Distal CBD cancer\
N = 21Chronic pancreatitis\
N = 5Serous cystadenoma and other benign diagnosis\
N = 6Age, years median (range)65.7 (37.4-81.3)64.9 (38.3-80.5)69.0 (54.3-74.4)64.7 (38.6-74.6)56.4 (43.8-68.2)60.6 (46.7-84.7)Gender Male60 (55%)37 (63%)5 (83%)11 (52%)5 (100%)2 (33%) Female50 (45%)22 (37%)1 (17%)10 (48%)04 (67%)ASA score112 (11%)9 (15%)02 (10%)1 (20%)0258 (53%)38 (66%)5 (83%)15 (75%)2 (40%)4 (80%)330 (27%)11 (19%)1 (17%)3 (15%)2 (40%)1 (20%)400000TNM-StageIA9 (8%)4 (7%)1 (17%)1 (5%)IB3 (3%)7 (12%)1 (17%)1 (5%)IIA27 (25%)6 (10%)2 (33%)7 (52%)IIB67 (65%)24 (41%)2 (33%)11 (33%)III016 (27%)01 (5%)Values are N (%). Numbers may not add up due to missing valuesNo clinical information is available from the patients with gastric cancer and the patients and healthy subjects from Heidelberg and Bergen

MiRNA purification from FFPE tissues {#Sec6}
------------------------------------

One FFPE block was selected from each patient for miRNA analysis. From each of these blocks, 3 10-μm sections were cut for miRNA extraction without micro-dissection. As method control, 9×3 sections were cut from a specimen from 1 of the PDAC patients. MiRNAs were extracted using Qiagen miRNeasy FFPE kit, Cat No./ID: 217504. Briefly, the sections were deparaffinized in xylene and ethanol and then treated with proteinase K, and RNA was isolated using the one-column spin column protocol for total RNA. The concentration of small RNAs was assessed by absorbance spectrometry on a DTX 880 (Beckman Coulter).

MiRNA analysis {#Sec7}
--------------

The following 46 miRNAs were selected for analysis: miR-21-5p, −23a-3p, −29a-5p, −31-5p, −34a-5p, −34c-5p, −93-3p, −122-5p, −125a-3p, −130b-3p, −135b-3p, −136-3p, −146a-5p, −148a-3p, −148a-5p, −155-5p, −186-5p, −187-3p, −194-3p, −196b-5p, −198, −203, −205-5p, −210, −212-3p, −216b, −217, −222-3p, −222-5p, −375, −411-5p, −431-5p, −450b-5p, −451a, −490-3p, −492, −509-5p, −571, −614, −622, −625-5p, −675-5p, −769-5p, −939, −944, and let-7 g. The selection was based on the previously described relationship of the miRNAs to PC in particular and to cancer biology in general (Detailed information on each specific miRNA is available in "Additional file [1](#MOESM1){ref-type="media"}").

The miRNAs were analyzed in triplicate using the Fluidigm BioMark System™. This system can perform multiple simultaneous real-time PCR measurements running gold-standard Taqman® assays in nanolitre quantities. The instructions from Fluidigm were followed in all details (<https://www.fluidigm.com>). The analyses were performed at AROS Applied Biotechnology A/S ([www.arosab.com](http://www.arosab.com), Aarhus, Denmark).

Statistical analysis {#Sec8}
--------------------

Differences in miRNA expression according to diagnosis were tested by univariate logistic regression including the raw miRNA expression level as continuous variables on the cycle threshold scale. Odds ratios (OR) per inter-quartile increase and 95% confidence intervals were computed for both PC vs. HS and PC vs. HS and CP.

Diagnostic indices were identified in 3 different ways among the significant miRNAs: (1) As a manually defined index by including 2 miRNA with OR \> 1 and 2 with OR \< 1 (indices I and IV);(2) As a computer generated index found by backwards elimination of a model with miRNAs chosen from 18 miRNAs described in an previous index (the so-called LASSO-classifier: miR-23a, 34c-5p, −122, −135b-3p, −136-3p, −186, −196b, −198, −203, −222-3p, −451, −490, −492, −509-5p, −571, −614, −622, and miR-93 \[[@CR27]\]) which were significant at a 1% significance level, to account for multiple testing and with less than 10% missing values (indices II and V) and (3) as a computer generated index like (2) but based on all significant miRNAs (indices III and VI). A total of 6 indices were identified: I, II, and III developed for the PC vs. HS comparison and IV, V, and VI developed for the PC vs. HS + CP comparison. The indices were evaluated by means of boxplots, and their performance was evaluated by computing sensitivity, specificity, accuracy, area under curve (AUC), true positives (TP), true negatives (TN), false positives (FP), and false negatives (FN). The indices were also tested on other cancer types. For each index, we first found a suitable cut-off by requiring a sensitivity of 85% in the PC vs. HS or vs. HS + CP comparison. Subsequently, this cut-off point was applied in all other comparisons.

It was not possible to stratify our patients according to TNM due to the very uneven distribution of cancer stages and resulting small subgroups.

For the prognostic study, the association between overall survival (OS) and miRNA expression was illustrated by Kaplan--Meier curves by dichotomizing the miRNA expression into below and above the median expression for each miRNA. The association was tested by means of univariate Cox proportional hazards regression both on the continuous variables and on the dichotomized variables, and presented as hazard ratios (HR) and corresponding 95% confidence intervals (CIs). In addition, analyses adjusted for age, sex, tumor stage, ASA score, and tumor differentiation were performed. Finally, we considered differences between 2 miRNAs at a time as a continuous variable in the Cox models (unadjusted and adjusted) for OS. Analyses were made for the diagnoses PDAC and A-AC together and separately.

In all analysis, the software package R version 3.1.1 (R Core Team 2014; R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. [www.R-project.org](http://www.r-project.org)) was used, and *P-*values below 5% were considered statistically significant.

Results {#Sec9}
=======

Diagnosis -- Pancreatic cancer vs. healthy subjects {#Sec10}
---------------------------------------------------

The following 14 miRNAs were upregulated in PC compared to HS: miR-21-5p, −23a-3p, −31-5p, −34c-5p, −93-3p, −135b-3p, −155-5p, −196b-5p, −203, −205-5p, −210, −222-3p, −451, and miR-622. The following 5 miRNAs were downregulated in PC: miR-122-5p, −130b-3p, −216b, − 217, and miR-375 (Table [2](#Tab2){ref-type="table"}).Table 2Significantly deregulated microRNAsmicroRNA upregulated in PC compared to healthy subjectsmiRNAOR (CI)*p*-valuePCHSMissingmiR-21-5p0.11 (0.03--0.25)0.00001341353miR-23a-3p0.36 (0.13--0.67)0.0100156539miR-31-5p0.38 (0.28--0.50)0.0000165350miR-34c-5p0.17 (0.09--0.28)0.0000165350miR-93-3p0.14 (0.06--0.26)0.0000165341miR-135b-3p0.31 (0.20--0.44)0.0000165305miR-155-5p0.11 (0.03--0.23)0.0000165332miR-196b-5p0.14 (0.02--0.45)0.0151147350miR-2030.37 (0.25--0.51)0.0000165350miR-205-5p0.71 (0.59--0.82)0.00001482131miR-2100.12 (0.05--0.22)0.0000165341miR-222-3p0.06 (0.02--0.15)0.0000165350miR-4510.14 (0.06--0.27)0.0000165350miR-6220.57 (0.41--0.76)0.0003165341microRNA downregulated in PC compared to healthy subjectsmiRNAOR (CI)*p*-valuePCHSMissingmiR-122-5p2.08 (1.40--3.51)0.00143018152miR-130b-3p5.34 (3.17--9.98)0.0000165350miR-216b6.30 (3.36--14.24)0.00001493516miR-2172.94 (2.03--4.69)0.00001423523miR-37526.10 (9.48--90.22)0.0000165350microRNA upregulated in PC compared to healthy subjects and chronic pancreatitismiRNAOR (CI)*p*-valuePCHS + CPMissingmiR-21-5p0.24 (0.14--0.36)0.00001344263miR-23a-3p0.54 (0.38--0.74)0.00031563152miR-31-5p0.50 (0.41--0.59)0.0000165740miR-34c-5p0.33 (0.25--0.43)0.0000165740miR-93-3p0.27 (0.17--0.400.0000165731miR-135b-3p0.31 (0.22--0.410.00001655816miR-155-5p0.46 (0.37--0.560.0000165722miR-186-5p0.71 (0.55--0.890.0041165740miR-196b-5p0.53 (0.39--0.700.00001472072miR-2030.36 (0.26--0.460.0000165740miR-205-5p0.79 (0.71--0.880.00001484645miR-2100.27 (0.18--0.360.0000165731miR-222-3p0.23 (0.16--0.320.0000165740miR-4510.44 (0.35--0.540.0000165740miR-4920.46 (0.22--0.780.0097574178miR-6140.75 (0.57--0.940.021911014115miR-6220.52 (0.41--0.660.0000165722microRNA downregulated in PC compared to healthy subjects and chronic pancreatitismiRNAOR (CI)*p*-valuePCHS + CPMissingmiR-122-5p1.99 (1.46--2.98)0.00013040169miR-130b-3p1.71 (1.33--2.23)0.0001165740miR-216b1.55 (1.34--1.84)0.00001497317miR-2171.46 (1.28--1.69)0.00001427126miR-3752.22 (1.62--3.15)0.0000165740

Three indices of miRNA expression, index I, II, and III, were identified to separate PC from HS (i.e., normal pancreas tissue):

\(I\) A manually defined index: miR-375 + miR-130b-3p -- miR-451 -- miR34c-5p.

\(II\) A computer-generated index based on univariate significant miRNAs chosen from 18 miRNAs describes in a previous index with less than 10% missing: 292.6458--3.0539×miR-34c-5p + 4.007×miR-203--10.4×miR-222-3p--3.6057×miR-451--4.3015×miR-622.

The potential miRNAs for index II were miR-34c-5p, −135-3p, −203, −222-3p, −451,and miR-622.

\(III\) A computer-generated index based on all univariate significant miRNAs with less than 10% missing values: 118.7249 + 77.2459×miR-130b-3p--23.7911×miR-34c-5p--49.923×miR-451.

The potential miRNAs for index III were miR-31-5p, −34c-5p,-93-3p, −130b-3p, −135b-3p, −155-5p, −203, −205-5p, −210, −216b, −217, −222-3p, −375, −451,and miR-622.

The performances of these indices are illustrated in box plots in Fig. [1](#Fig1){ref-type="fig"} and Table [3](#Tab3){ref-type="table"} (upper part). The manually calculated index I was able to separate PC from HS with a sensitivity of 84.9 (CI 78.5--90.0), but could also differentiate the other malignant diagnoses from HS, with a sensitivity varying from 66.7 (distal CBD cancer) to 100.0 (DC and GC). The computer-generated index II performed in the same way with regard to PC vs. HS, but was inferior for separating the other malignancies from HS except for distal CBD cancer, where it performed better than index I. The computer-generated index III performed slightly better than index II with regard to separating A-AC and DC cancer from HS, but was inferior for separating distal CBD cancer and GC.Fig. 1Performance of diagnostic indices for PC vs. HS and for PC vs. HS + CP Table 3Performance of diagnostic indicesStudyIndexDesigned sensitivitycutoffSensitivity (CI)Specificity (CI)Accuracy (CI)AUC (CI)TPTNFPFNPerformance of diagnostic indices developed on PC vs. HSPC vs. HSI0.85−9.1384.85 (78.45--89.95)100.00 (90.00--100.00)87.50 (82.10--91.74)1.00 (1.00--1.00)14035025A-AC vs. HSI−9.1374.58 (61.56--85.02)100.00 (90.00--100.00)84.04 (75.05--90.78)0.99 (0.96--1.00)4435015DC vs. HSI−9.13100.00 (54.07--100.00)100.00 (90.00--100.00)100.00 (91.40--100.00)1.00 (1.00--1.00)63500CBD vs. HSI−9.1366.67 (43.03--85.41)100.00 (90.00--100.00)87.50 (75.93--94.82)1.00 (0.99--1.00)143507A-AC, DC, CBD vs. HSI−9.1374.42 (63.87--83.22)100.00 (90.00--100.00)81.82 (73.78--88.24)0.99 (0.97--1.00)6435022GC vs. HSI−9.13100.00 (83.16--100.00)100.00 (90.00--100.00)100.00 (93.51--100.00)1.00 (1.00--1.00)203500PC vs. HSII0.8516.6884.85 (78.45--89.95)100.00 (90.00--100.00)87.50 (82.10--91.74)1.00 (1.00--1.00)14035025A-AC vs. HSII16.6867.80 (54.36--79.38)100.00 (90.00--100.00)79.79 (70.25--87.37)0.94 (0.89--0.98)4035019DC vs. HSII16.6883.33 (35.88--99.58)100.00 (90.00--100.00)97.56 (87.14--99.94)1.00 (1.00--1.00)53501CBD vs. HSII16.6880.95 (58.09--94.55)100.00 (90.00--100.00)92.86 (82.71--98.02)0.97 (0.90--1.00)173504A-AC, DC, CBD vs. HSII16.6872.09 (61.38--81.23)100.00 (90.00--100.00)80.17 (71.94--86.86)0.95 (0.91--0.99)6235024GC vs. HSII16.6895.00 (75.13--99.87)100.00 (90.00--100.00)98.18 (90.28--99.95)0.96 (0.87--1.00)193501PC vs. HSIII0.85149.1084.85 (78.45--89.95)100.00 (90.00--100.00)87.50 (82.10--91.74)1.00 (1.00--1.00)14035025A-AC vs. HSIII149.1072.88 (59.73--83.64)100.00 (90.00--100.00)82.98 (73.84--89.95)0.98 (0.95--1.00)4335016DC vs. HSIII149.1066.67 (22.28--95.67)100.00 (90.00--100.00)95.12 (83.47--99.40)1.00 (1.00--1.00)43502CBD vs. HSIII149.1071.43 (47.82--88.72)100.00 (90.00--100.00)89.29 (78.12--95.97)1.00 (0.99--1.00)153506A-AC, DC, CBD vs. HSIII149.1072.09 (61.38--81.23)100.00 (90.00--100.00)80.17 (71.94--86.86)0.99 (0.97--1.00)6235024GC vs. HSIII149.10100.00 (83.16--100.00)100.00 (90.00--100.00)100.00 (93.51--100.00)1.00 (1.00--1.00)203500Performance of diagnostic indices developed on PC vs. HS + CPPC vs. HS + CPIV0.85−9.1384.85 (78.45--89.95)75.68 (64.31--84.90)82.01 (76.54--86.66)0.89 (0.84--0.94)140561825A-AC vs. HS + CPIV−9.1374.58 (61.56--85.02)75.68 (64.31--84.90)75.19 (66.96--82.26)0.83 (0.76--0.90)44561815DC vs. HS + CPIV−9.13100.00 (54.07--100.00)75.68 (64.31--84.90)77.50 (66.79--86.09)0.85 (0.76--0.93)6561804 vs. HS + CPIV−9.1366.67 (43.03--85.41)75.68 (64.31--84.90)73.68 (63.65--82.19)0.80 (0.71--0.88)1456187A-AC, DC, CBD vs. HS + CPIV−9.1374.42 (63.87--83.22)75.68 (64.31--84.90)75.00 (67.55--81.50)0.83 (0.76--0.89)64561822CG vs. HS + CPIV−9.13100.00 (83.16--100.00)75.68 (64.31--84.90)80.85 (71.44--88.24)0.97 (0.93--1.00)2056180PC vs. HS + CPV0.851.3884.85 (78.45--89.95)91.89 (83.18--96.97)87.03 (82.10--91.01)0.96 (0.94--0.98)14068625A-AC vs. HS + CPV1.3877.97 (65.27--87.71)91.89 (83.18--96.97)85.71 (78.59--91.17)0.93 (0.87--0.97)4668613DC vs. HS + CPV1.38100.00 (54.07--100.00)91.89 (83.18--96.97)92.50 (84.39--97.20)1.00 (0.98--1.00)66860CBD vs. HS + CPV1.3885.71 (63.66--96.95)91.89 (83.18--96.97)90.53 (82.78--95.58)0.94 (0.89--0.98)186863A-AC, DC, CBD vs. HS + CPV1.3881.40 (71.55--88.98)91.89 (83.18--96.97)86.25 (79.93--91.18)0.94 (0.89--0.97)7068616GC vs. HS + CPV1.3895.00 (75.13--99.87)91.89 (83.18--96.97)92.55 (85.26--96.95)0.99 (0.96--1.00)196861PC vs. HS + CPVI0.851.4684.85 (78.45--89.95)93.24 (84.93--97.77)87.45 (82.57--91.37)0.97 (0.95--0.99)14069525A-AC vs. HS + CPVI1.4672.88 (59.73--83.64)93.24 (84.93--97.77)84.21 (76.88--89.95)0.92 (0.87--0.96)4369516DC vs. HS + CPVI1.46100.00 (54.07--100.00)93.24 (84.93--97.77)93.75 (86.01--97.94)0.99 (0.97--1.00)66950CBD vs. HS + CPVI1.4676.19 (52.83--91.78)93.24 (84.93--97.77)89.47 (81.49--94.84)0.93 (0.87--0.98)166955A-AC, DC, CBD vs. HS + CPVI1.4675.58 (65.13--84.20)93.24 (84.93--97.77)83.75 (77.10--89.10)0.93 (0.89--0.96)6569521GC vs. HS + CPVI1.4675.00 (50.90--91.34)93.24 (84.93--97.77)89.36 (81.30--94.78)0.91 (0.80--0.98)156955*AUC* Area under Curve, *TP* True positive, *TN* True negative, *FP* False positive, *FN* False negative, *PC* Pancreatic Cancer, *A-AC* Ampullary Adenocarcinoma, *DC* Duodenal Cancer, *CBD* Common bile duct cancer, *GC* Gastric cancer, *HS* Healthy subjects

Diagnosis - Pancreatic cancer vs. healthy subjects + chronic pancreatitis {#Sec11}
-------------------------------------------------------------------------

The following 17 miRNAs were upregulated in PDAC compared with benign specimens (HS and CP combined): miR-21-5p, −23a-3p, −31-5p, −34c-5p, −93-3p, −135b-3p, −155-5p, −186-5p, −196b-5p, −203, −205-5p, −210, −222-3p, −451, −492, −614, and miR-622. The following 5 miRNAs were downregulated in PDAC compared to benign specimens (HS and CP combined): miR-122-5p, −130b-3p, −216b, −217, and miR-375 (Table [2](#Tab2){ref-type="table"}).

Three indices, IV, V, and VI, of miRNA expression to separate PC from benign tissue (i.e., HS and CP combined) were identified.

\(IV\) A manually defined index: miR-375 + miR-130b-3p -- miR-451 -- miR-34c-5p.

\(V\) A computer-generated index based on significant miRNAs chosen from 18 miRNAs described in a previous index with less than 10% missing values: 20.5487--1.5899×miR-222-3p--0.4006×miR-451--0.3864×miR-203--0.5056×miR-622+ 1.203×miR-186-5p.

The potential miRNAs for index V weremiR-34c-5p, −135b-3p, −186-5p, −203, −222-3p, −451, and miR-622.

\(VI\) A computer-generated index based on all significant miRNAs with less than 10% missing values: 7.1834--0.5175×miR-210 + 1.3893×miR-93-3p -- 0.7423×miR-375--2.6184×miR-222-3p -- 0.3414×miR-451--0.3852×miR-203--0.5316×miR-622 + 1.822×miR-186-5p.

The potential miRNAs for index VI were miR-31-5p, −34c-5p, −93-3p, −130b-3p, −135b-3p, −155-5p, −186-5p, −203, −210, −216b, −217, −222-3p, −375, −451, and miR-622.

The performances of these indices are illustrated in box plots in Fig. [1](#Fig1){ref-type="fig"} and in Table [3](#Tab3){ref-type="table"} (lower part). Index IV could separate HS from the other diagnoses. Indices V and VI were able to separate CP from the malignant diagnoses.

Diagnostic miRNA indices previously identified for pancreatic cancer {#Sec12}
--------------------------------------------------------------------

We have previously described the following 4 different diagnostic miRNA indices in FFPE cancer tissues consisting of 2 different miRNAs \[[@CR27]\]: (1) miR-196b-5p -- miR-217; (2) miR-411 -- miR-198; (3) miR-614 -- miR-122-5p; and (4) miR-614 -- miR-93-3p. The performance of the 4 indices in the present cohort was tested using the Fluidigm method. Since many samples had non-detectable miRNAs, we only used observations that were non-missing, i.e., not imputed by a large C~t~-value. Index 1 had 97 samples with at least 1miRNA missing, index 2 had 122 samples with at least 1 miRNA missing, index 3 had 213 samples with at least 1 miRNA missing, and index 4 had 115 samples with at least 1miRNA missing. For indices 2 and 3, it was not possible to consider HS alone. The performances of these indices are shown in box plots in Fig. [2](#Fig2){ref-type="fig"}. Index 1 could separate HS from PC patients but could not separate CP from A-AC. Index 1 could separate GC from all other diagnoses with high accuracy. Indices 2, 3, and 4 could not separate samples with benign from malignant diagnoses. Further information is given in the "Additional file [2](#MOESM2){ref-type="media"}".Fig. 2Performance of two miRNA diagnostic indices

Prognostic miRNAs -- PDAC and A-AC patients combined {#Sec13}
----------------------------------------------------

In all, 157 patients with either PDAC or A-AC were available for the survival analysis, and 112died during the follow-up period. Table [4](#Tab4){ref-type="table"} illustrates that low expression of 6 miRNAs (miR-29a-5p, miR-34a-5p, miR-125a-3p, miR-146a-5p, miR-205-5p, and miR-212-3p) was associated with short OS, both with and without adjustment for age, sex, tumor stage/differentiation, and ASA-score. When patients were divided into 2 groups for each miRNA (defined as expression under or above the median level), low miR-34a-5p, miR-205-5p, miR-212-3p, and miR-222-5plevels were significantly associated with short OS. After adjusting for age, sex, tumor stage/differentiation, and ASA-score, let-7 g, miR-29a-5p, miR-34a-5p, miR-205-5p, and miR-212-3p were associated with short OS. Figure [3](#Fig3){ref-type="fig"} illustrates Kaplan--Meier curves for the6 miRNAs reaching a significance level below 0.01.Table 4Prognostic miRNAs in patients with PC + A-AC, PC and A-ACPDAC and A-ACCT-expression (per IQR increase)UnadjustedAdjustedmiRNAHR (CI)PNHR (CI)PNmiR-29a-5p0.87 (0.76--0.99)0.03021560.85 (0.74--0.98)0.0212145miR-34a-5p0.66 (0.54--0.81)\<0.00011560.64 (0.52--0.79)\<0.0001145miR-125a-3p0.83 (0.73--0.95)0.00511530.83 (0.72--0.95)0.0077142miR-146a-5p0.87 (0.76--0.99)0.02961570.85 (0.74--0.97)0.0191146miR-205-5p0.91 (0.86--0.96)4e-041300.92 (0.87--0.97)0.0037120miR-212-3p0.81 (0.72--0.91)4e-041560.80 (0.71--0.91)4e-04145Under median vs. over medianUnadjustedAdjustedmiRNAHR (CI)PNHR (CI)PNlet-7 gNS0.62 (0.41--0.93)0.0220145miR-29a-5pNS0.64 (0.42--0.96)0.0314145miR-34a-5p0.46 (0.31--0.67)\<0.00011560.47 (0.31--0.71)0.0003145miR-205-5p0.37 (0.25--0.57)\<0.00011300.44 (0.28--0.69)0.0003120miR-212-3p0.51 (0.35--0.74)5e-041560.53 (0.35--0.79)0.0021145miR-222-5p0.68 (0.47--1.00)0.0495152NSPDACCT-expression (per IQR increase)UnadjustedAdjustedmiRNAHR (CI)PNHR (CI)PNmiR-34a-5p0.72 (0.56--0.93)0.01041030.70 (0.52--0.93)0.014493miR-212-3p0.83 (0.71--0.99)0.03281030.82 (0.68--0.99)0.035093Under median vs. over medianUnadjustedAdjustedmiRNAHR (CI)PNHR(CI)PNmiR-34a-5p0.49 (0.31--0.77)0.00201030.53 (0.32--0.89)0.015193miR-212-3p0.64 (0.41--0.98)0.04171030.59 (0.36--0.97)0.035893A-ACCT-expression (per IQR increase)UnadjustedAdjustedmiRNAHR (CI)PNHR (CI)PNlet-7 g0.74 (0.58--0.93)0.010053NSmiR-34a-5p0.66 (0.46--0.94)0.0218530.58 (0.38--0.89)0.012152miR-1871.51 (1.01--2.24)0.0439242.34 (1.22--4.48)0.010424miR-205-5p0.73 (0.63--0.86)0.000137NSmiR-450b-5pNS0.48 (0.23--0.99)0.045826Under median vs. over medianUnadjustedAdjustedmiRNAHR (CI)PNHR (CI)PNmiR-34a-5p0.40 (0.19--0.86)0.0183530.36 (0.16--0.85)0.019552*NS* Not significant Fig. 3Kaplan--Meier curves for miRNAs significantly associated to survival in patients with PC + A-AC

Table [5](#Tab5){ref-type="table"} shows 30 and 27 combinations of 2 miRNAs significantly associated with short OS in an unadjusted and an adjusted analysis in PDAC and A-AC in combination.Table 5Differences of miRNAUnadjusted effects on differencesAdjusted effects on differencesmiRNA1miRNA2HR (CI)PNmiRNA1miRNA2HR (CI)PNPDAC + AACmiR-148amiR-212-3p1.20 (1.09--1.33)0.0002155miR-34a-5pmiR-148a0.82 (0.73--0.92)0.0011144miR-205-5pmiR-769-5p0.90 (0.85--0.95)0.0003129miR-205-5pmiR-769-5p0.91 (0.85--0.96)0.0015119miR-148amiR-205-5p1.08 (1.04--1.13)0.0004130miR-146a-5pmiR-212-3p1.33 (1.11--1.60)0.0017145miR-34a-5pmiR-148a0.83 (0.75--0.92)0.0009155miR-34a-5pmiR-1870.67 (0.52--0.88)0.003844miR-34a-5pmiR-1870.64 (0.50--0.83)0.000947miR-148amiR-205-5p1.07 (1.02--1.12)0.004120miR-146a-5pmiR-212-3p1.32 (1.12--1.57)0.0013156miR-29a-5pmiR-205-5p1.08 (1.03--1.15)0.0046119miR-187miR-212-3p1.55 (1.18--2.04)0.001647miR-125a-3pmiR-769-5p0.81 (0.69--0.94)0.0071140miR-34a-5pmiR-769-5p0.74 (0.62--0.89)0.0017154miR-187miR-212-3p1.47 (1.11--1.96)0.007844miR-212-3pmiR-769-5p0.81 (0.70--0.92)0.0020154let-7 gmiR-1870.74 (0.59--0.93)0.008544miR-205-5pmiR-625-5p0.91 (0.86--0.97)0.002372miR-146a-5pmiR-205-5p1.08 (1.02--1.14)0.0097120miR-205-5pmiR-450b-5p0.91 (0.86--0.97)0.003194miR-205-5pmiR-222-5p0.93 (0.87--0.99)0.0152117miR-146a-5pmiR-205-5p1.08 (1.03--1.14)0.0033130miR-29a-5pmiR-769-5p0.81 (0.68--0.96)0.0171143miR-205-5pmiR-222-5p0.92 (0.86--0.97)0.0034127let-7 gmiR-205-5p1.07 (1.01--1.13)0.018120let-7 gmiR-205-5p1.08 (1.02--1.14)0.0048130miR-29a-5pmiR-194-3p0.68 (0.50--0.94)0.018846miR-194-3pmiR-205-5p1.26 (1.07--1.48)0.006236miR-125a-3pmiR-1870.76 (0.61--0.96)0.018843miR-29a-5pmiR-205-5p1.07 (1.02--1.13)0.0072129let-7 gmiR-212-3p1.14 (1.02--1.28)0.0233144miR-125a-3pmiR-205-5p1.08 (1.02--1.15)0.0074128miR-125a-3pmiR-205-5p1.07 (1.01--1.14)0.0236118let-7 gmiR-1870.82 (0.70--0.95)0.009347miR-205-5pmiR-450b-5p0.93 (0.87--0.99)0.02485miR-34a-5pmiR-205-5p1.07 (1.02--1.13)0.0125130miR-34a-5pmiR-194-3p0.64 (0.43--0.94)0.026245miR-125a-3pmiR-148a0.90 (0.83--0.98)0.0139152miR-194-3pmiR-212-3p1.39 (1.04--1.85)0.027345miR-125a-3pmiR-769-5p0.84 (0.73--0.97)0.0146151miR-212-3pmiR-625-5p0.86 (0.75--0.98)0.029874miR-125a-3pmiR-1870.80 (0.66--0.96)0.015546miR-34a-5pmiR-205-5p1.07 (1.01--1.13)0.0307120miR-212-3pmiR-625-5p0.87 (0.77--0.98)0.019479miR-194-3pmiR-205-5p1.21 (1.02--1.45)0.032633let-7 gmiR-212-3p1.12 (1.01--1.25)0.0332155miR-625-5pmiR-9441.51 (1.03--2.22)0.033920miR-187miR-194-3p1.41 (1.02--1.96)0.036621miR-125a-3pmiR-148a0.91 (0.84--1.00)0.0383141miR-205-5pmiR-212-3p0.95 (0.90--1.00)0.0410130miR-146a-5pmiR-769-5p0.84 (0.71--1.00)0.0394144miR-34a-5pmiR-625-5p0.88 (0.78--1.00)0.044379miR-34a-5pmiR-625-5p0.87 (0.75--1.00)0.047874miR-146a-5pmiR-1870.79 (0.63--1.00)0.045247miR-187miR-205-5p1.12 (1.00--1.26)0.046838miR-34a-5pmiR-146a-5p0.83 (0.68--1.00)0.0488156PDACmiR-148amiR-212-3p1.18 (1.04--1.33)0.0077103miR-34a-5pmiR-769-5p0.63 (0.47--0.84)0.00292miR-34a-5pmiR-148a0.86 (0.76--0.97)0.0156103miR-29a-5pmiR-1871.99 (1.20--3.29)0.007220miR-34a-5pmiR-769-5p0.75 (0.59--0.96)0.0199102miR-187miR-769-5p0.54 (0.33--0.87)0.011120miR-146a-5pmiR-212-3p1.26 (1.01--1.56)0.0371103miR-187miR-205-5p0.72 (0.56--0.94)0.013819miR-34a-5pmiR-146a-5p0.74 (0.56--0.99)0.0427103miR-212-3pmiR-769-5p0.75 (0.60--0.95)0.015392miR-148amiR-212-3p1.18 (1.03--1.34)0.01693miR-450b-5pmiR-9441.56 (1.06--2.30)0.024324miR-34a-5pmiR-148a0.86 (0.75--0.99)0.034193miR-146a-5pmiR-212-3p1.29 (1.02--1.63)0.034393miR-148amiR-431-5p1.32 (1.02--1.72)0.036434miR-146a-5pmiR-1871.57 (1.01--2.44)0.043820miR-222-5pmiR-769-5p0.84 (0.70--1.00)0.049192A-ACmiR-205-5pmiR-769-5p0.71 (0.60--0.84)*\<*0.000136miR-34a-5pmiR-769-5p0.51 (0.32--0.81)0.004351miR-34a-5pmiR-1870.44 (0.27--0.72)0.001124miR-125a-3pmiR-1870.37 (0.18--0.75)0.005523miR-148amiR-205-5p1.25 (1.09--1.44)0.001837miR-34a-5pmiR-1870.48 (0.28--0.82)0.006724miR-125a-3pmiR-1870.69 (0.54--0.88)0.003223miR-148amiR-1870.59 (0.40--0.87)0.007424miR-187miR-205-5p1.35 (1.10--1.66)0.004117miR-29a-5pmiR-769-5p0.65 (0.48--0.89)0.007752miR-187miR-212-3p2.22 (1.29--3.82)0.004224miR-222-5pmiR-450b-5p2.12 (1.18--3.81)0.012325miR-205-5pmiR-450b-5p0.73 (0.59--0.91)0.004522miR-187miR-769-5p2.09 (1.16--3.78)0.014824let-7 gmiR-205-5p1.28 (1.07--1.52)0.00637miR-29a-5pmiR-1870.62 (0.42--0.91)0.015424miR-146a-5pmiR-205-5p1.19 (1.05--1.34)0.006537miR-187miR-212-3p2.23 (1.16--4.30)0.01624let-7 gmiR-769-5p0.74 (0.59--0.93)0.008352miR-146a-5pmiR-1870.54 (0.33--0.90)0.017524miR-34a-5pmiR-769-5p0.66 (0.48--0.91)0.012252miR-148amiR-450b-5p2.12 (1.14--3.96)0.018126miR-34a-5pmiR-205-5p1.22 (1.04--1.43)0.012637miR-450b-5pmiR-769-5p0.31 (0.12--0.84)0.021426let-7 gmiR-1870.77 (0.62--0.95)0.01724miR-34a-5pmiR-625-5p0.71 (0.52--0.96)0.026730let-7 gmiR-625-5p0.74 (0.58--0.95)0.017531miR-125a-3pmiR-769-5p0.75 (0.58--0.97)0.028349miR-125a-3pmiR-205-5p1.21 (1.03--1.43)0.022736miR-29a-5pmiR-625-5p0.74 (0.56--0.99)0.040830let-7 gmiR-222-5p0.80 (0.67--0.97)0.024250miR-205-5pmiR-222-5p0.81 (0.66--0.99)0.043633miR-29a-5pmiR-1870.74 (0.56--0.97)0.027224miR-205-5pmiR-212-3p0.86 (0.75--0.98)0.028937miR-146a-5pmiR-1870.67 (0.46--0.96)0.030824miR-187miR-769-5p1.47 (1.02--2.11)0.036724miR-450b-5pmiR-769-5p0.59 (0.35--1.00)0.048927

Prognostic miRNAs - PDAC {#Sec14}
------------------------

One hundred three patients with PDAC were available for the survival analysis, and 83 died during the follow-up period. In both the unadjusted and the adjusted (age, sex, tumor stage/differentiation, ASA-score) analyses, low expression of 2 miRNAs was associated with short OS prognosis:miR-34a-5p: HR = 0.72(CI: 0.56--0.93) (unadjusted) and HR = 0.70(CI: 0.52--0.93) (adjusted); and miR-212-3p HR = 0.83(CI: 0.71--0.99) (unadjusted) and HR = 0.82(CI: 0.68--0.99) (adjusted). Dividing the patients into 2 groups for each miRNA (defined as expression under or above the median level), low miR-34a-5p and miR-212-3p levels were associated with short OS. Figure [4](#Fig4){ref-type="fig"} shows Kaplan--Meier curves for the miRNAs reaching a significance level below 0.01.Fig. 4Kaplan--Meier curves for miRNAs significantly associated to survival in patients with PC and patients with A-AC

Table [5](#Tab5){ref-type="table"} shows 5 and 12 combinations of 2 miRNAs significantly associated with short OS in an unadjusted and an adjusted analysis in PDAC.

Prognostic miRNAs -- A-AC {#Sec15}
-------------------------

Fifty-four patients with A-AC were available for the survival analysis, and 29 died during the follow-up period. In the unadjusted analysis, 4 miRNAs were significantly associated with prognosis: let-7 g: HR = 0.74(CI: 0.58--0.93), miR-34a-5p: HR = 0.66(CI: 0.46--0.94), miR-187: HR = 1.51(CI: 1.01--2.24), and miR-205-5p: HR = 0.74(CI: 0.63--0.86). In the adjusted analysis (age, sex, tumor stage/differentiation, ASA-score), low expression of miR-34a-5p: HR = 0.58(CI: 0.38--0.89) and miR-450b-5p: HR = 0.48(CI: 0.23--0.99) and high expression of miR-187: HR = 2.34(CI: 1.22--4.48) were associated with short OS. When patients were divided into 2 groups for each miRNA (defined as expression under or above the median level), low expression of miR-34a-5p was associated with short OS. Figure [4](#Fig4){ref-type="fig"} shows Kaplan--Meier curves for the miRNAs reaching a significance level below 0.01.

Table [5](#Tab5){ref-type="table"} shows 21 and 16 combinations of 2 miRNAs in A-AC FFPE tissue significantly associated with short OS in both an unadjusted and an adjusted analysis.

Discussion {#Sec16}
==========

In the present study, our aim was to validate previously described tissue miRNA expression profiles as diagnostic and prognostic biomarkers of PC and other periampullary cancers \[[@CR20]--[@CR32]\]. We used non-microdissected FFPE tissue from 165 patients who had undergone surgery for PDAC and from 86 patients who had undergone resection for other periampullary cancers.

Many of the diagnostic miRNAs described in the literature \[[@CR20], [@CR21], [@CR34]\] could be validated. We found the following miRNAs either upregulated or downregulated in PC tissue compared to tissue from CP and/or normal pancreas, upregulated miRNAs: miR-21-5p, −23a-3p, −31-5p, −34c-5p, −93-3p, −135b-3p, −155-5p, −186-5p, −196b-5p, −203, −205-5p, −210, −222-3p, −451, −492, −614, and miR-622; and downregulated miRNAs: miR-122-5p, −130b-3p, −216b, −217, and miR-375. Furthermore, we validated the two-miRNA index "miR-196b -- miR-217" \[[@CR27]\], and suggested new diagnostic indices for separating patients with PC vs. HS and PC vs. HS and CP combined. We found that these indices were useful in discriminating other upper gastrointestinal cancers (duodenal cancer, common bile duct cancer and gastric cancer) from normal pancreas and CP.

In addition to the diagnostic miRNAs, we demonstrated the association of 10 miRNAs with prognosis and constructed several indices based on differences of 2 miRNA associated with poor prognosis.

A major limitation of the study was the high number of non-detectable miRNAs using the Fluidigm BioMark System™. Even though we purified the miRNAs from FFPE by the same method as in our previous studies \[[@CR27], [@CR31]\] and repeated the analysis several times, we still experienced a high number of undetectable miRNAs. At present, we have no explanation for this problem apart from possible platform sensitivity limitations.

We consider it a strength of the study that non-microdissected samples were used, since this will also be the case in a clinical setting. The tumor microenvironment is a highly dynamic component of PC, often constitutes the bulk of the tumor, and should therefore be taken into account. The extracellular stroma participates in paracrine signaling that promotes PDAC cell survival and metastasis, and the dense extracellular matrix characteristic of PDAC acts as a physical barrier to infiltrating immune cells and the diffusion of chemotherapy \[[@CR35]--[@CR37]\]. MicroRNAs are involved in the regulation of the extracellular components in different tissues \[[@CR38], [@CR39]\]. Since many studies regarding miRNAs in PC are performed on microdissected tissue or cell lines the miRNAs originating from the extracellular stroma are less elucidated. The following miRNAs significantly deregulated in the present study are known to be related to the extracellular compartment of PC: miR-21, −29, −130b, −210, and-451 \[[@CR40]--[@CR43]\].

Among the validated miRNAs, high expression of miR-21, miR-31, and miR-155 and low expression of miR-217 and miR-375are the most consistently described dysregulated miRNAs in PC. Several studies have found miR-155to be upregulated in PC \[[@CR20]--[@CR22], [@CR28], [@CR32], [@CR44], [@CR45]\]. miR-155 functions as an onco-miRNA in different types of cancer,e.g., breast, cervix, colon, and lung cancer, and high miR-155 expression in cancer tissue is associated with poor prognosis in PC and lung cancer \[[@CR30], [@CR46]--[@CR49]\]. The oncogenic effect of miR-155 maybe caused by the targeting of anti-inflammatory signal pathways such as Sh2 domain-containing inositol phosphatase-1 (Ship1) or from suppression of cytokine signaling 1 (Socs1) \[[@CR50], [@CR51]\].

miR-21 is also an onco-miR involved in PC tumorigenesis, invasion, metastasis, and chemoresistance \[[@CR20], [@CR21], [@CR23], [@CR27], [@CR32], [@CR44], [@CR45], [@CR52]--[@CR57]\]. miR-21 is primarily upregulated in the extracellular stroma, which is considered a dynamic component of PC, and high expression is associated with poor prognosis \[[@CR40]\]. Our study was conducted on non-microdissected tissue and thus also detects miRNAs in the extracellular stroma.miR-21 targets tumor suppressors like PTEN, PDCD4, and TIMP3, components of the p53 pathway, and modulates TGF-b signaling, thus promoting cell proliferation, survival, and migration/invasion \[[@CR45], [@CR58]--[@CR60]\].

miR-31 is upregulated in PC \[[@CR21], [@CR27], [@CR28], [@CR45], [@CR61]\]. miR-31 targets human mutL homolog 1 (a mismatch repair protein) \[[@CR62]\] and activates the RAS pathway by inhibiting RAS p21 GTPase activating protein 1 (RASA1) in colorectal cancer \[[@CR63]\].

miR-217 is downregulated in PC and in pancreatic intraepithelial neoplasm (PanIN) \[[@CR21], [@CR27], [@CR28], [@CR32], [@CR45], [@CR64]\]. This finding has also been replicated in studies using fine needle aspirates from PC \[[@CR24], [@CR65]\].miR-217 acts as a tumor suppressor in PC by targeting *KRAS* \[[@CR66]\] and is involved in epithelial-mesenchymal-transition (EMT) in PC and CP via the miR-217-SIRT1 pathway, which can be triggered by TGF-β1 in inflammatory processes \[[@CR67]\].

miR-375 is downregulated in PC compared to normal pancreas, is associated with prognosis, and can differentiate between pancreatobiliary and intestinal subtypes in ampullary adenocarcinoma \[[@CR20], [@CR21], [@CR27], [@CR28], [@CR32], [@CR68]\]. miR-375 is also downregulated in esophageal, gastric, breast, lung, colorectal, and cervical cancers \[[@CR69]--[@CR74]\]. miR-375 plays a role in the development and maintenance of the α- and β-cell mass in the normal pancreas and is upregulated in patients with type 2 diabetes \[[@CR75], [@CR76]\].miR-375 targets 3-phosphoinositide-dependent protein kinase-1 (PDK1) in PC and inhibits PC cell proliferation in vitro \[[@CR77], [@CR78]\].

In the literature, the following miRNAs are described as prognostic after PC resection:Let-7 g, miR-21, miR-29a-5p, miR-34a-5p, miR-146a, miR-155, miR-196a, miR-203, miR-205, miR-210, miR-212, miR-222, miR-450b-5p, and miR-675 \[[@CR23], [@CR29]--[@CR32]\]. We have previously described prognostic indices using combinations of high expression of miR-212 and miR-675 and low expression of miR-148a-5p (previous ID: miR-148a\*), miR-187 and let-7 g-3p (previous ID: let-7 g\*) in FFPE tissue from patients operated for PC \[[@CR31]\]. Only a few of these patients received adjuvant chemotherapy after surgery. In the present study, patients with PDAC and A-AC were all treated with adjuvant gemcitabine for 6 months or until disease recurrence. In this population, we could validate let-7 g, miR-29a-5p, miR-34a-5p, miR-146a-5p,miR-205-5p, and miR-212-3pas prognostic biomarkers after radical resection for PC.

The let-7 family of miRNAs includes tumor suppressor miRNAs, the expression of which is prognostic in HCC, gastric, and ovarian cancers \[[@CR79]--[@CR81]\]. Let-7 g is involved in pathways essential for the development of cancer. It targets Fas and is involved in Fas-mediated apoptosis \[[@CR82]\]. Silencing of let-7b/g activates AKT signaling and promotes carcinogenesis in gastric cancer \[[@CR83]\]. Let-7 inhibits cell motility in breast cancer by regulating genes in the cytoskeleton pathway and silencing of let-7 promotes metastases \[[@CR84]\]. Let-7 inhibits proliferation in HCC by downregulation of c-Myc and upregulation of p16(INK4A) \[[@CR85]\].

In PC, miR-29a-5p induces EMT, stimulates pancreatic stellate cells to accumulate protein in the extracellular matrix, and increases resistance to gemcitabine through the Wnt/beta-catenin pathway \[[@CR41], [@CR86], [@CR87]\]. miR-34a is upregulated in cervical and colorectal cancers and downregulated in breast, prostate, renal and lung cancer \[[@CR49], [@CR88]\].

The miR-34 family miRNAs are described as tumor suppressor miRNAs, and miR-34a/c suppresses breast cancer invasion and metastasis by targeting Fos-related antigen-1 \[[@CR89]\]. PC mouse models show that miR-146a acts through EGFR signaling \[[@CR90]\]. miR-205 is involved in EMT and acts through the anti-apoptotic protein Bcl-2 (in prostate cancer) and HER3 (in breast cancer) \[[@CR91]--[@CR93]\]. We found that low expression of miR-125a-3p was associated with short OS in patients with PC, and this is a novel observation.miR-125a-3p has been described as a tumor suppressor miRNA in several cancers \[[@CR94], [@CR95]\].

In the present study, miR-130b was found to be downregulated in PDAC compared to benign specimens. Interestingly, this miRNA is upregulated in the stroma compared to carcinoma cells \[[@CR42]\].

Further information about the 46 miRNAs analyzed in the present study is given in "Additional file [1](#MOESM1){ref-type="media"}".

Conclusions {#Sec18}
===========

In conclusion, we could validate miRNAs selected from the literature as diagnostic and/or prognostic biomarkers in patients radically resected for PC. No microdissection of the tumors was done, and some of the miRNAs most likely originated from the stroma and not the cancer cells. The diagnostic ability of these miRNAs was also tested on duodenal cancer, common bile duct cancer, and gastric cancer -- diagnoses that represent a considerable diagnostic challenge in separating from PC in a clinical setting. Hopefully, this study can contribute to the understanding of pancreatic and periampullary cancers and improve the diagnosis, prognosis, and ultimately treatment of patients with these conditions. For example, this could be achieved by allocating young patients with a miRNA expression profile suggestive of poor prognosis to a more aggressive chemotherapy regimen, or elderly patients with a more promising prognostic profile could be spared from adjuvant therapy.

Additional files {#Sec17}
================

Additional file 1:Background on all measured microRNA. (DOCX 1012 kb) Additional file 2:All statistical calculations including insignificant results not presented in the manuscript. (DOC 1481 kb)
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:   Common bile duct
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:   microRNA
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